BR112018073642A2 - toe imaging immunomodulators - Google Patents

toe imaging immunomodulators

Info

Publication number
BR112018073642A2
BR112018073642A2 BR112018073642-2A BR112018073642A BR112018073642A2 BR 112018073642 A2 BR112018073642 A2 BR 112018073642A2 BR 112018073642 A BR112018073642 A BR 112018073642A BR 112018073642 A2 BR112018073642 A2 BR 112018073642A2
Authority
BR
Brazil
Prior art keywords
immunomodulators
imaging
toe
toe imaging
milamolecules
Prior art date
Application number
BR112018073642-2A
Other languages
Portuguese (pt)
Inventor
J. DONNELLY David
M. Boy Kenneth
Zhang Yunhui
Kim Joonyoung
Pena Adrienne
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112018073642A2 publication Critical patent/BR112018073642A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12Arrangements for detecting or locating foreign bodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se à síntese e uso de milamoléculas marcadas com 18f para realizar imagiologia de vários processos que ocorrem no interior do corpo, para detectar o local de moléculas associadas a patologia de doença e monitorar o progresso da doença.The present invention relates to the synthesis and use of 18f-labeled milamolecules to perform imaging of various processes occurring within the body, to detect the location of disease pathology-associated molecules and to monitor disease progress.

BR112018073642-2A 2016-05-19 2017-05-17 toe imaging immunomodulators BR112018073642A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
US62/338,872 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
BR112018073642A2 true BR112018073642A2 (en) 2019-02-26

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073642-2A BR112018073642A2 (en) 2016-05-19 2017-05-17 toe imaging immunomodulators

Country Status (24)

Country Link
US (2) US11103605B2 (en)
EP (2) EP3458111B1 (en)
JP (1) JP6953444B2 (en)
KR (1) KR102378288B1 (en)
CN (1) CN109414514B (en)
AU (1) AU2017268291B2 (en)
BR (1) BR112018073642A2 (en)
CA (1) CA3024844A1 (en)
CY (1) CY1124241T1 (en)
DK (1) DK3458111T3 (en)
EA (1) EA038019B1 (en)
ES (1) ES2864091T3 (en)
HR (1) HRP20210644T8 (en)
HU (1) HUE054306T2 (en)
IL (1) IL262962B (en)
LT (1) LT3458111T (en)
MA (1) MA53402A (en)
MX (1) MX2018014028A (en)
PL (1) PL3458111T3 (en)
PT (1) PT3458111T (en)
RS (1) RS61742B1 (en)
SG (1) SG11201810177VA (en)
SI (1) SI3458111T1 (en)
WO (1) WO2017201111A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019012986A2 (en) * 2016-12-23 2019-12-03 Univ Johns Hopkins tumor and immune cell imaging based on pd-11 expression
EA201991673A1 (en) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
JP7304846B2 (en) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ANTI-CD8 ANTIBODY AND USES THEREOF
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (en) * 2019-07-30 2022-06-10 哈尔滨医科大学 Preparation and application method of tracer
WO2021188480A1 (en) * 2020-03-16 2021-09-23 Bristol-Myers Squibb Company Immunomodulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
DE69737867T2 (en) 1996-05-03 2007-10-18 Immunomedics, Inc. TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
DE69738353T2 (en) 1996-07-12 2009-09-24 Immunomedics, Inc. RADIOMETALL-BINDING PEPTIDE ANALOG
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
CA2302360C (en) 1997-09-03 2005-11-15 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
EP2141175B1 (en) 2007-03-26 2016-07-27 The University of Tokyo Process for synthesizing cyclic peptide compound
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (en) 2010-09-09 2015-11-18 国立大学法人 東京大学 Translational construction and search for active species of special peptide compound library containing N-methylamino acid and other special amino acids
WO2012074130A1 (en) 2010-12-03 2012-06-07 国立大学法人東京大学 Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
RU2014143443A (en) 2012-03-29 2016-05-20 Ориджин Дискавери Текнолоджиз Лимитед IMMUNOMODULATING CYCLE COMPOUNDS
JP2013253842A (en) 2012-06-06 2013-12-19 Univ Of Tokyo Screening method for peptide connected to target molecule depending on ph
ES2647076T3 (en) 2012-06-06 2017-12-19 Polyphor Ag Beta fork peptidomimetics
EP3633377A1 (en) 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105813640A (en) 2013-09-06 2016-07-27 奥瑞基尼探索技术有限公司 Cyclic peptidomimetic compounds as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
EP3191113B1 (en) 2014-09-11 2019-11-06 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ES2941895T3 (en) 2014-11-25 2023-05-26 Bristol Myers Squibb Co Methods and Compositions for 18F Radiolabeling of the Fibronectin Type (III) Domain
US10406251B2 (en) * 2014-11-25 2019-09-10 Bristol-Myers Squibb Company PD-L1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
ES2910832T3 (en) 2016-11-07 2022-05-13 Bristol Myers Squibb Co Immunomodulators
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
CN109414514A (en) 2019-03-01
SG11201810177VA (en) 2018-12-28
EP3458111A1 (en) 2019-03-27
KR102378288B1 (en) 2022-03-23
AU2017268291A1 (en) 2019-01-17
US11103605B2 (en) 2021-08-31
CY1124241T1 (en) 2022-07-22
PL3458111T3 (en) 2021-06-28
MA53402A (en) 2021-06-02
JP2019520328A (en) 2019-07-18
AU2017268291B2 (en) 2022-09-29
RS61742B1 (en) 2021-05-31
EA038019B1 (en) 2021-06-23
IL262962B (en) 2020-04-30
EA201892635A1 (en) 2019-04-30
PT3458111T (en) 2021-04-09
JP6953444B2 (en) 2021-10-27
IL262962A (en) 2018-12-31
ES2864091T3 (en) 2021-10-13
DK3458111T3 (en) 2021-04-26
EP3458111B1 (en) 2021-03-03
SI3458111T1 (en) 2021-07-30
US20190117801A1 (en) 2019-04-25
HRP20210644T1 (en) 2021-05-28
CA3024844A1 (en) 2017-11-23
LT3458111T (en) 2021-05-25
MX2018014028A (en) 2019-04-04
WO2017201111A1 (en) 2017-11-23
HUE054306T2 (en) 2021-08-30
KR20190009330A (en) 2019-01-28
HRP20210644T8 (en) 2021-06-25
EP3827849A1 (en) 2021-06-02
CN109414514B (en) 2022-03-11
US20210386876A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
BR112018073642A2 (en) toe imaging immunomodulators
BR112017010414A2 (en) methods and compositions for 18f radiolabeling of biological substances
BR112017009497A2 (en) aadc polynucleotides for the treatment of parkinson's disease
SV2017005426A (en) DERIVATIVES OF PHENILTRIAZOL REPLACED WITH HYDROXIALQUIL AND ITS USES
CL2015000717A1 (en) Compounds derived from bicyclic pyridinones and their salts; pharmaceutical composition that includes them; and its use for the treatment of neurodegeneration and psychiatric disorders, which include Alzheimer's disease or Niemann-pick type C disease.
BR112016018062A8 (en) therapeutic compounds, pharmaceutical composition and uses
CR20160485A (en) CYCLOPROPANAMINE COMPOUND AND ITS USES
CR20160537A (en) 3-QUINASA DELTA PHOSFOINOSYTI INHIBITOR FOR MEDICAL USE
CL2014000806A1 (en) Compounds derived from 1-arylcarbonyl-4-oxy-piperidino; pharmaceutical composition that includes them; Use for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis.
BR112016025819A2 (en) adeno-associated virus vectors for the treatment of lysosomal deposition diseases
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
BR112018072545A2 (en) arginase inhibitors and their therapeutic applications
BR112019009172A2 (en) formulations for radiotherapy and diagnostic imaging.
BR112016016274A2 (en) BLOOD-BRAIN BARRIER BRIDGE
CL2015000615A1 (en) Compounds derived from 4-amino-quinolines, rip2 kinase inhibitors; pharmaceutical composition that includes them; use for the treatment of diseases such as crohn's disease, ulcerative colitis or blau syndrome.
CL2018000597A1 (en) Methods to treat inflammatory diseases
GT201700058A (en) 1-ALKYL-6-OXO-1,6-DIHYDROPYRIDIN-3-ILO COMPOUNDS AND USES THEREOF
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
BR112017012381A2 (en) immunotherapy for angiogenic disease
BR112015019873A2 (en) macrocyclic lrrk2 kinase inhibitors
BR112016017620A2 (en) STEROIDAL COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
BR112017011543A2 (en) cd44v6-derived cyclic peptides for the treatment of cancers and angiogenesis-related diseases
IL266778A (en) Combined assay for the differential diagnosis of the alzheimer's disease
BR112017002675A2 (en) methods for improving myocardial performance in fontan patients using udenafil compositions
BR112017003334A2 (en) disintegrin variants and pharmaceutical uses of these

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]